Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Sentagliptin combined with metformin in the treatment of patients with type 2 diabetes

Next Previous
Search
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Sentagliptin combined with metformin in the treatment of patients with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Dec 2024 According to a CGeneTech media release, company announced that National Medical Products Administration (NMPA) of China announced that Sengagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China based on the results of phase 3 study.
    • 05 Dec 2024 Results presented in a CGeneTech Media Release.
    • 20 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top